Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Radiological Assessments Clear all
Recruiting Phase 2 Interventional

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

NCT05825066
View directory record Official record
Conditions
Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Nab paclitaxel, Gemcitabine, Radiological Assessments, mFOLFIRINOX
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT07001748
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
78
States / cities
Irvine, California • Los Angeles, California • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Recruiting No phase listed Observational

Evaluation and Treatment of Neurosurgical Disorders

NCT00060541
View directory record Official record
Conditions
Neurologic Disorders
Interventions
Laboratory tests, Radiological exams
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
4 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Not applicable Interventional

Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function

NCT06081127
View directory record Official record
Conditions
Breast Cancer
Interventions
MOve-ABC, Enhanced Usual Care
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 2, 2026, 6:50 AM EDT
Completed No phase listed Observational

Clinical Outcomes Following Glenoid Neck Fracture as Correlated With Quantitative Assessment of Osseous Injury

NCT00644813
View directory record Official record
Conditions
Scapula Fracture, Glenoid; Fracture
Interventions
Scapular with glenoid neck fractures
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
12
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Ann Arbor, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

NCT03474107
View directory record Official record
Conditions
Ureteral Cancer, Urothelial Cancer, Bladder Cancer
Interventions
Enfortumab Vedotin, Docetaxel, Vinflunine, Paclitaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
25
States / cities
Orange, California • Sacramento, California • Whittier, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 1 Interventional

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

NCT03267836
View directory record Official record
Conditions
Meningioma, Meningioma, Adult
Interventions
Avelumab, Proton Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 2, 2026, 6:50 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Hematologic Malignancies

NCT06636175
View directory record Official record
Conditions
Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Interventions
64Cu-LLP2A, PET/CT
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

NCT01887717
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere®, Sorafenib
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas

NCT00766753
View directory record Official record
Conditions
Malignant Glioma
Interventions
Dendritic vaccine pulsed with multiple peptides, The first booster vaccine phase:, The second booster vaccine phase:
Biological
Lead sponsor
Frank Lieberman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 2, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC

NCT06693323
View directory record Official record
Conditions
HNSCC, Head and Neck Squamous Cell Carcinoma
Interventions
AHCC®capsules
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 79 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 2, 2026, 6:50 AM EDT
Recruiting No phase listed Observational

Prospective Analysis of Spinal Epidural Abscess

NCT05464251
View directory record Official record
Conditions
Spinal Epidural Abscess
Interventions
Prospective chart review of subjects diagnosed with spinal epidural abscess
Other
Lead sponsor
Francis Farhadi
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

NCT00668148
View directory record Official record
Conditions
Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma, Leiomyosarcoma, Adipocytic Sarcoma, Synovial Sarcoma
Interventions
IMC-A12 (cixutumumab)
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Aurora, Colorado • Orlando, Florida • Metairie, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 2, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

NCT06058988
View directory record Official record
Conditions
Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent Glioblastoma
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

NCT04022213
View directory record Official record
Conditions
Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma
Interventions
131 I-omburtamab, WAP-IMRT
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Reference Values for Videofluoroscopic Measures of Swallowing

NCT05497219
View directory record Official record
Conditions
Dysphagia, Oropharyngeal
Interventions
Videofluoroscopic Swallowing Study (VF)
Diagnostic Test
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Completed No phase listed Observational

Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery

NCT01417507
View directory record Official record
Conditions
Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Cognitive/Functional Effects, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Seizure
Interventions
cognitive assessment, magnetic resonance imaging, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Procedure · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 2, 2026, 6:50 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers

NCT02375841
View directory record Official record
Conditions
Brain Cancer, Glioblastoma
Interventions
psychometric tests, questionnaires and neurocognitive assessments
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
8
States / cities
Detroit, Michigan • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radiological Evaluation of Radiesse Implantation in the Hands

NCT02949921
View directory record Official record
Conditions
Volume Loss in the Dorsum of the Hand
Interventions
Radiesse injectable implant and 2% lidocaine HCL
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 2, 2026, 6:50 AM EDT
Not listed Phase 2 Interventional Results available

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

NCT00874614
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Ultratrace® Iobenguane I131
Radiation
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 2, 2026, 6:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Development of an Intrauterine Pressure Threshold to Confirm Tubal Occlusion

NCT04071392
View directory record Official record
Conditions
Sterilization, Female, Fallopian Tube Occlusion
Interventions
Hysterosalpingogram (HSG)
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

NCT01392209
View directory record Official record
Conditions
Brain Cancer, MALIGNANT GLIOMA, Glioblastoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Anaplastic Oligo-astrocytoma (AOA), Anaplastic Mixed Gliomas, Malignant Glioma NOS
Interventions
Bevacizumab & Stereotactic Radiotherapy
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
5
States / cities
San Francisco, California • Basking Ridge, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

NCT02335944
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Capmatinib, Nazartinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 2, 2026, 6:50 AM EDT